Osteosarcoma

被引:205
作者
Messerschmitt, Patrick J. [1 ]
Garcia, Ryan M. [1 ]
Abdul-Karim, Fadi W. [2 ]
Greenfield, Edward M. [1 ]
Getty, Patrick J. [1 ,3 ,4 ]
机构
[1] Case Western Reserve Univ, Dept Orthopaed Surg, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Pathol, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA
[4] Louis Stokes VA Hosp Cleveland, Dept Orthopaed Oncol, Cleveland, OH USA
关键词
HIGH-GRADE OSTEOSARCOMA; SCANDINAVIAN-SARCOMA-GROUP; HIGH-DOSE METHOTREXATE; STUDY-GROUP PROTOCOLS; NEOADJUVANT CHEMOTHERAPY; OSTEOGENIC-SARCOMA; PROGNOSTIC-FACTORS; LIMB-SALVAGE; NONMETASTATIC OSTEOSARCOMA; PERIOSTEAL OSTEOSARCOMA;
D O I
10.5435/00124635-200908000-00005
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Osteosarcoma, the most common bone sarcoma, affects approximately 560 children and adolescents annually in the United States. The incidence of new diagnoses peaks in the second decade of life. Twenty percent of patients present with clinically detectable metastases, with micrometastases presumed to be present in many of the remaining patients. Treatment typically includes preoperative chemotherapy, surgical resection, and postoperative chemotherapy. Limb-salvage procedures with wide surgical margins are the mainstay of surgical intervention. Advances in chemotherapy protocols have led to a 5-year survival rate of 60% to 78%. Among the goals of future treatment regimens are improved chemotherapeutic agents with higher specificity and lower toxicity.
引用
收藏
页码:515 / 527
页数:13
相关论文
共 65 条
  • [41] Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
    Meyers, PA
    Schwartz, CL
    Krailo, M
    Kleinerman, ES
    Betcher, D
    Bernstein, ML
    Conrad, E
    Ferguson, W
    Gebhardt, M
    Goorin, AM
    Harris, MB
    Healey, J
    Huvos, A
    Link, M
    Montebello, J
    Nadel, H
    Nieder, M
    Sato, J
    Siegal, G
    Weiner, M
    Wells, R
    Wold, L
    Womer, R
    Grier, H
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) : 2004 - 2011
  • [42] CHEMOTHERAPY FOR NONMETASTATIC OSTEOGENIC-SARCOMA - THE MEMORIAL SLOAN-KETTERING EXPERIENCE
    MEYERS, PA
    HELLER, G
    HEALEY, J
    HUVOS, A
    LANE, J
    MARCOVE, R
    APPLEWHITE, A
    VLAMIS, V
    ROSEN, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 5 - 15
  • [43] Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
    Meyers, Paul A.
    Schwartz, Cindy L.
    Krailo, Mark D.
    Healey, John H.
    Bernstein, Mark L.
    Betcher, Donna
    Ferguson, William S.
    Gebhardt, Mark C.
    Goorin, Allen M.
    Harris, Michael
    Kleinerman, Eugenie
    Link, Michael P.
    Nadel, Helen
    Nieder, Michael
    Siegal, Gene P.
    Weiner, Michael A.
    Wells, Robert J.
    Womer, Richard B.
    Grier, Holcombe E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 633 - 638
  • [44] Telangiectatic osteosarcoma: Radiologic-pathologic comparison
    Murphey, MD
    Jaovisidha, SW
    Temple, HT
    Gannon, FH
    Jelinek, JS
    Malawer, MM
    [J]. RADIOLOGY, 2003, 229 (02) : 545 - 553
  • [45] Nakajima H, 1997, CANCER, V79, P2095, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2095::AID-CNCR6>3.0.CO
  • [46] 2-O
  • [47] *NAT CANC I, 2009, CLIN TRIALS
  • [48] National Air and Space Intelligence Center, 2009, NCCN CLIN PRACT GUID, P14
  • [49] NICHTER LS, 1993, ORTHOP CLIN N AM, V24, P511
  • [50] Okada K, 1999, CANCER, V85, P1044, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1044::AID-CNCR6>3.0.CO